Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 8:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kidney Transplant Recipients Clear all
Recruiting Phase 1 Interventional

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465
View directory record Official record
Conditions
Cytomegalovirus Prophylaxis
Interventions
Letermovir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 8:36 PM EDT
Withdrawn No phase listed Observational

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

NCT04216303
View directory record Official record
Conditions
Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions
hemoglobin A1c
Diagnostic Test
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

A Study of Oral Valcyte (Valganciclovir) in Pediatric Kidney Transplant Recipients

NCT01376804
View directory record Official record
Conditions
Kidney Transplantation, Cytomegalovirus Infections
Interventions
valganciclovir [Valcyte]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
4 Months to 16 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
4
States / cities
Gainesville, Florida • Los Angeles, Louisiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Jun 10, 2026, 8:36 PM EDT
Recruiting Phase 3 Interventional

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

NCT06798909
View directory record Official record
Conditions
Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
Interventions
Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jun 10, 2026, 8:36 PM EDT
Completed No phase listed Observational

The TOGETHER Project - Kidney

NCT03873623
View directory record Official record
Conditions
Kidney Transplant Rejection
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 6, 2022 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation and Management of Metabolic Bone Disease in Kidney Transplant Recipients

NCT03958409
View directory record Official record
Conditions
Skeletal Anomalies, Kidney Transplant; Complications
Interventions
measurements to evaluate metabolic bone disease, standard care
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA Investigational Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
10
States / cities
Phoenix, Arizona • Chicago, Illinois • Lexington, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jun 10, 2026, 8:36 PM EDT
Completed No phase listed Observational

Quality of Life in Pediatric Transplant Recipients

NCT00209196
View directory record Official record
Conditions
Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Heart-Lung Transplantation
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
11 Years to 18 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2015 · Synced Jun 10, 2026, 8:36 PM EDT
Not listed Phase 4 Interventional

Web Based Renal Transplant Patient Medication Education

NCT00327483
View directory record Official record
Conditions
Renal Transplant Recipients
Interventions
Internet based education software
Behavioral
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
14 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 17, 2006 · Synced Jun 10, 2026, 8:36 PM EDT
Enrolling by invitation Not applicable Interventional

Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT06336863
View directory record Official record
Conditions
Kidney Transplant Immunosuppression
Interventions
Allosure and TruGraf, Immunosuppression Taper
Diagnostic Test · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 10, 2026, 8:36 PM EDT
Completed No phase listed Observational

Long-term Follow-up of Spare the Nephron (STN) Patients

NCT01126333
View directory record Official record
Conditions
Kidney Transplant
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Not applicable Interventional

Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients

NCT01776073
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Patient Navigation
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Jun 10, 2026, 8:36 PM EDT
Enrolling by invitation Phase 2 Interventional

Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

NCT05285878
View directory record Official record
Conditions
Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection, Kidney Transplant Failure, Kidney Failure, Chronic, Graft Rejection
Interventions
Fingolimod, Placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Not applicable Interventional

Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants

NCT00007787
View directory record Official record
Conditions
Kidney Transplantation, Chronic Allograft Nephropathy
Interventions
Cyclosporine, Anti-human thymocyte globulin (rabbit), Tacrolimus
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
21 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Jun 10, 2026, 8:36 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients

NCT02463253
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 82 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

Ciprofloxacin for Prevention of BK Infection

NCT01789203
View directory record Official record
Conditions
BK Virus Infection
Interventions
Ciprofloxacin, placebo
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Early Phase 1 Interventional

Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients

NCT03249194
View directory record Official record
Conditions
Kidney Transplant, Hepatitis C
Interventions
Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Jun 10, 2026, 8:36 PM EDT
Recruiting No phase listed Observational

Proteogenomic Monitoring and Assessment of Kidney Transplant Recipients

NCT01531257
View directory record Official record
Conditions
Acute Rejection (AR) of Transplanted Kidney, Chronic Allograft Nephropathy (CAN), Interstitial Fibrosis (IF), Tubular Atrophy (TA)
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients

NCT00771745
View directory record Official record
Conditions
Renal Transplant Rejection, Transplants and Implants
Interventions
Thymoglobulin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 17, 2016 · Synced Jun 10, 2026, 8:36 PM EDT
Completed No phase listed Observational

CellCept/Iron Study: The Iron Ion-Mycophenolate Mofetil Chelation Complex Interaction in Renal Allograft Recipients

NCT00227045
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 19, 2007 · Synced Jun 10, 2026, 8:36 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

NCT02866695
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ingenol mebutate gel 0.015%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jun 10, 2026, 8:36 PM EDT
Withdrawn Phase 4 Interventional

Mechanism of Hypertension Treatments in Liver Transplant Recipients (BLOCK LTR-HTN)

NCT05275907
View directory record Official record
Conditions
High Blood Pressure, Liver Transplant, Renal Function Abnormal
Interventions
Amlodipine Besylate, Chlorthalidone
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Jun 10, 2026, 8:36 PM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

NCT06824454
View directory record Official record
Conditions
Hypophosphatemia, Kidney Transplantation
Interventions
Dipyridamole 75 MG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Jun 10, 2026, 8:36 PM EDT